Margin trendWarning
영업외손익 급변 (영업이익 대비 82% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
DuChemBIO
A176750 · KOSDAQ₩5,680+4.41%
2026-08-03 closeLoading chart…
Close
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Why this signalSignal guide
Cross
Death Cross (5_20, 0d ago)
Moving-average alignment
No
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p
Beat the market on 62.1% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Valuation in its own history
PER 19.2 · PBR 3.57 — own history (2014-12~) percentiles 100/100 · 100/100
PER100/100
PBR100/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 3.84
Distress
Grey
Safe
- Altman Z''
- 3.84
- Beneish M-Score
- -2.21
- Sloan accrual
- 1.48%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
7/9Strong
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score7/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginPass
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 14.3%
- Interest coverage
- 4.7x
- Return on equity (ROE)
- 18.6%
Operating margin −5pp
TolerableInterest coverageBase 4.7x adverse case 3x
Return on equity (ROE)Base 18.6% adverse case 5.1%
Revenue −15%
TolerableInterest coverageBase 4.7x adverse case 4x
Return on equity (ROE)Base 18.6% adverse case 7.5%
Interest rate +2pp
TolerableInterest coverageBase 4.7x adverse case 3.3x
Return on equity (ROE)Base 18.6% adverse case 8.2%
Interest coverage limit
Current margin 11.2ppInterest coverage limit at an operating margin of 3.1%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-18Suppliers disclosed by the company in its 2026-03-18 annual report.
Suppliers without disclosed amount
USDEURAUDWaterSyntheraFASTLABVIZAMYLCASSETTEFDGDUOCITRATECASSETTESterileVacuum+11 more
Financials at a glance
DuChemBIO's latest results and balance sheet. The bars track the last three periods.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 지오영60.96%2024-12-27 · 증감 -2.93%p
Connections
AI-extracted related companies · for reference
Suppliers
Customers
삼성서울병원서울대학교병원아산병원
Competitors
Same theme
대한핵의학회의료영상진단바이오마커 진단
Recent filings
DuChemBIO's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy